Losartan Potassium

Phase 2Small molecule

Losartan Potassium is a small molecule that works as a Type-1 Angiotensin II Receptor Antagonist.[2] It is being investigated across 11 indications, with its most advanced program in Phase 2.[1]

Losartan Potassium is one of 368 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

367

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderActive, not recruiting

Kidney DiseaseUnknown

Diabetic NephropathyUnknown

Chronic Kidney DiseaseUnknown

Type 2 Diabetes MellitusUnknown

StrokeUnknown

Genetic PolymorphismCompleted

MemoryActive, not recruiting

ARTRecruiting

Emotional ProcessingRecruiting

Post-Traumatic Stress DisorderPreclinical

Active, not recruiting

Kidney DiseasePreclinical

Unknown

Diabetic NephropathyPreclinical

Unknown

Chronic Kidney DiseasePreclinical

Unknown

Type 2 Diabetes MellitusPreclinical

Unknown

StrokePreclinical

Unknown

Genetic PolymorphismPreclinical

Completed

MemoryPreclinical

Active, not recruiting

ARTPhase 1

Recruiting

Emotional ProcessingPhase 1

Recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Losartan Potassium

Merck & Co.

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

PD-1 Blocking Antibody

SSun Yat-sen University

Preclinical

1 9

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT04539808

Clinical

Trials by Indication[1]

Hypertension8 trials

Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Completed·OOrganon and Co·Phase 3·NCT00756938·101 enrolled

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01302691·327 enrolled

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Terminated·OOrganon and Co·Phase 3·NCT00447603·40 enrolled

Show 5 more trials

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00857285·130 enrolled

Matão Controlling Hypertension (MatCH Study): Rationale and Design

Unknown status·CCentro Neurológico de Pesquisa e Reabiitação, Brazil·Phase 1·NCT03147092·15,000 enrolled

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Terminated·WWake Forest University Health Sciences·Phase 2·NCT01234922·6 enrolled

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00888355·428 enrolled

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00886600·122 enrolled

ART5 trials

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions

Completed·RRoxane Laboratories·N/A·NCT01216852·40 enrolled

Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

Completed·OOrganon and Co·Phase 1·NCT00953680·77 enrolled

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT01216878·40 enrolled

Show 2 more trials

Losartan and Emotional Learning

Recruiting·UUniversity of Oxford·Phase 1·NCT06628154·60 enrolled

Losartan and Social Processing

Recruiting·UUniversity of Oxford·Phase 1·NCT06624904·68 enrolled

Memory2 trials

Losartan and Emotional Memory

Completed·UUniversity of Oxford·N/A·NCT03763409·53 enrolled

Losartan and Memory

Completed·UUniversity of Oxford·N/A·NCT05828940·41 enrolled

Blood Pressure2 trials

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Completed·OOrganon and Co·Phase 1·NCT00943852·13 enrolled

AVE7688 in Patients With Mild to Moderate Blood Pressure

Completed· Sanofi logo

Sanofi·Phase 2/3·NCT00284128·1,940 enrolled

MACE2 trials

Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01218698

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01218022

23 more indications

Hypertensive2 trials

A Study to Investigate the Antihypertensive Efficacy of MK0954

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00887250·366 enrolled

Olmesartan Comparison to Losartan in Hypertensive Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT00949884·941 enrolled

Angiotensin Converting Enzyme1 trial

Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial

Unknown status·AArmed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi·Phase 1·NCT05132712·100 enrolled

Tics1 trial

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

Completed·YYaounde Central Hospital·Phase 4·NCT04222686·23 enrolled

Emotional Processing1 trial

Losartan and Emotional Processing in Young People

Recruiting·UUniversity of Oxford·Phase 1·NCT06636812·60 enrolled

Allograft1 trial

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

Completed·OOrganon and Co·Phase 4·NCT00140907·367 enrolled

Pediatric NAFLD1 trial

Losartan for the Treatment of Pediatric NAFLD

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03467217·83 enrolled

Atherosclerosis1 trial

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

Completed·OOrganon and Co·Phase 4·NCT00496834·201 enrolled

Marfan syndrome1 trial

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Completed·CCarelon Research·Phase 3·NCT00429364·608 enrolled

Fasting Conditions1 trial

A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions

Completed·PPharmtechnology LLC·Phase 1·NCT03459911·66 enrolled

Interaction1 trial

The Pharmacokinetic Interaction Between Amlodipine and Losartan

Completed·KKorea University Anam Hospital·Phase 1·NCT03912285·24 enrolled

Trial1 trial

SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)

Completed·OOrganon and Co·Phase 3·NCT00739674·992 enrolled

Glomerulonephritis1 trial

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Unknown status·—·Phase 4·NCT02063100·720 enrolled

Eosinophilic Esophagitis1 trial

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Completed·—·Phase 2·NCT03029091·15 enrolled

Essential Hypertension1 trial

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00856271·287 enrolled

Effectiveness1 trial

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Completed·—·Phase 2·NCT01808196·6 enrolled

Overweight1 trial

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT00185094·60 enrolled

Proteinuria1 trial

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Completed·OOrganon and Co·Phase 3·NCT00568178·306 enrolled

Genetic Polymorphism1 trial

Antihypertensive Response to Losartan and Genetic Polymorphisms

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00617877·800 enrolled

Efficacy and Safety1 trial

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00882440·576 enrolled

Pancreatic Cancer1 trial

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT04539808·42 enrolled

Preeclampsia1 trial

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Completed·—·Phase 1·NCT04632589·11 enrolled

Metabolism1 trial

Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies

Completed·HHospital General de Niños Pedro de Elizalde·Phase 4·NCT05402397·40 enrolled

Borderline Resectable Pancreatic Adenocarcinoma1 trial

SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer

Completed·UUniversity of Utah·Phase 1·NCT04106856·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for Losartan Potassium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Losartan Potassium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Losartan Potassium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Type-1 Angiotensin II Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Losartan Potassium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hypertension8 trials

ART5 trials

Memory2 trials

Blood Pressure2 trials

MACE2 trials

Hypertensive2 trials

Angiotensin Converting Enzyme1 trial

Tics1 trial

Emotional Processing1 trial

Allograft1 trial

Pediatric NAFLD1 trial

Atherosclerosis1 trial

Marfan syndrome1 trial

Fasting Conditions1 trial

Interaction1 trial

Trial1 trial

Glomerulonephritis1 trial

Eosinophilic Esophagitis1 trial

Essential Hypertension1 trial

Effectiveness1 trial

Overweight1 trial

Proteinuria1 trial

Genetic Polymorphism1 trial

Efficacy and Safety1 trial

Pancreatic Cancer1 trial

Preeclampsia1 trial

Metabolism1 trial

Borderline Resectable Pancreatic Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News